Socioeconomic Disparities in Survival After Hodgkin Lym*
霍奇金淋巴瘤后生存的社会经济差异*
基本信息
- 批准号:7003259
- 负责人:
- 金额:$ 7.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-01 至 2007-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Hodgkin Lymphoma (HL) is 1 of the most common cancers of young adults and, because of successful treatment strategies, is generally considered curable for this age group at all stages of disease. Treatment, however, is associated with significant sequelae such that survivors experience some of the highest rates of second primary cancers, HL recurrences, and radiation-induced cardiac disease, with associated mortality. This outcome is particularly tragic considering the young age of most HL patients and the potential years of life lost following HL. Our preliminary data, and limited other prior research, have revealed disparities in HL survival by socioeconomic status (SES), particularly in young adults. Therefore, utilizing California Cancer Registry (CCR) patient data enhanced by geographic linkage with US Census SES data and with hospital and physician characteristics, we will undertake an efficient, cost-effective, population-based secondary data analysis to examine the effects of neighborhood SES on long-term survival following HL. Specifically, we will evaluate both overall survival (which takes into account death associated with HL, treatment sequelae and non-cancer events) and HL-specific survival, after considering patient characteristics, including race/ethnicity and histologic subtype, and markers of health care. We also will compare the survival experience of HL patients to that of comparable non-cancer patients (relative survival), adjusted for neighborhood SES and within specific racial/ethnic groups. These analyses will include demographic, clinical and tumor data for all (n = -3,800) HL cases newly diagnosed throughout California during 1988-1992 and reported to the population-based CCR; a neighborhood SES composite index derived from the 1990 US Census based on the patient's residence at diagnosis; hospital characteristics from the American Hospital Association; and 10-15 years of vital-status follow-up information. For these survival analyses, we will use multivariate adjusted Cox proportional hazards modeling and SEER*Stat software and stratify analyses by age and race/ethnicity. The study's overall objective is to document SES disparities in long-term survival following HL in an unbiased, population-based, and racially and ethnically diverse case series that will yield generalizable and thus interpretable results. If this study finds survival disparities, it will provide the foundation and impetus for more targeted studies to investigate the likely complex explanatory mechanisms, such as variation in access to and quality of care, incidence of side effects and management of long-term health, and health behaviors, stated goals of the NCI. By evaluating SES disparities in long-term survival, this study is an important first step in overcoming such disparities by helping inform decision-makers about specific populations in whom the length and quality of life can be improved following HL diagnoses.
描述(由申请人提供):霍奇金淋巴瘤(HL)是年轻人最常见的癌症之一,由于成功的治疗策略,通常认为该年龄组在疾病的所有阶段都是可治愈的。然而,治疗与显著的后遗症相关,例如幸存者经历了一些最高的第二原发性癌症、HL复发和辐射诱导的心脏病的发生率,以及相关的死亡率。考虑到大多数HL患者的年龄较小以及HL后潜在的寿命损失,该结局尤其悲惨。我们的初步数据,以及有限的其他先前研究,揭示了HL生存的社会经济地位(SES)的差异,特别是在年轻人。因此,利用加州癌症登记处(CCR)的患者数据,通过与美国人口普查SES数据的地理联系以及医院和医生的特征进行增强,我们将进行一项有效的、具有成本效益的、基于人群的二级数据分析,以检查社区SES对HL后长期生存的影响。具体而言,我们将在考虑患者特征(包括人种/种族和组织学亚型)以及医疗保健标志物后,评价总生存期(考虑与HL相关的死亡、治疗后遗症和非癌症事件)和HL特异性生存期。我们还将比较HL患者与可比的非癌症患者的生存经验(相对生存期),调整了社区SES和特定种族/民族组。这些分析将包括所有受试者的人口统计学、临床和肿瘤数据。(n =-3,800)1988-1992年期间在整个加州新诊断并报告给基于人群的CCR的HL病例;基于患者诊断时居住地的1990年美国人口普查得出的社区SES复合指数;来自美国医院协会的医院特征;以及10-15年的生命状态随访信息。对于这些生存分析,我们将使用多变量调整的考克斯比例风险模型和SEER*Stat软件,并按年龄和人种/种族进行分层分析。该研究的总体目标是在一个无偏倚、基于人群、种族和人种多样的病例系列中记录HL后长期生存的SES差异,从而产生可推广的结果。如果这项研究发现了生存差异,它将为更有针对性的研究提供基础和动力,以调查可能的复杂解释机制,例如获得和护理质量的变化,副作用的发生率和长期健康管理,以及健康行为,NCI的既定目标。通过评估SES在长期生存方面的差异,这项研究是克服这种差异的重要的第一步,帮助决策者了解HL诊断后可以改善生活长度和质量的特定人群。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Disparities in survival after Hodgkin lymphoma: a population-based study.
- DOI:10.1007/s10552-009-9382-3
- 发表时间:2009-12
- 期刊:
- 影响因子:2.3
- 作者:Keegan, Theresa H. M.;Clarke, Christina A.;Chang, Ellen T.;Shema, Sarah J.;Glaser, Sally L.
- 通讯作者:Glaser, Sally L.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theresa H M Keegan其他文献
Patient-reported outcomes in cancer care – hearing the patient voice at greater volume
癌症护理中患者报告的结果——以更大的音量听到患者的声音
- DOI:
10.1038/sj.bdj.2018.723 - 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Ashley Wilder Smith;Keith M Bellizzi;Theresa H M Keegan;Brad Zebrack;Vivien W Chen;A. Neale;Ann S. Hamilton;M. Shnorhavorian;Charles F Lynch - 通讯作者:
Charles F Lynch
Theresa H M Keegan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theresa H M Keegan', 18)}}的其他基金
Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer Population
项目 3:AYA 癌症人群的慢性疾病和后期影响
- 批准号:
10658904 - 财政年份:2020
- 资助金额:
$ 7.06万 - 项目类别:
Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer Population
项目 3:AYA 癌症人群的慢性疾病和后期影响
- 批准号:
10263882 - 财政年份:2020
- 资助金额:
$ 7.06万 - 项目类别:
Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer Population
项目 3:AYA 癌症人群的慢性疾病和后期影响
- 批准号:
10477012 - 财政年份:2020
- 资助金额:
$ 7.06万 - 项目类别:
Incidence of Malignancies in Californians with Sickle Cell Disease
患有镰状细胞病的加利福尼亚人的恶性肿瘤发病率
- 批准号:
9170720 - 财政年份:2016
- 资助金额:
$ 7.06万 - 项目类别:
The influence of the built environment on outcomes after breast cancer
建筑环境对乳腺癌术后预后的影响
- 批准号:
7878062 - 财政年份:2009
- 资助金额:
$ 7.06万 - 项目类别:
The influence of the built environment on outcomes after breast cancer
建筑环境对乳腺癌术后预后的影响
- 批准号:
7739114 - 财政年份:2009
- 资助金额:
$ 7.06万 - 项目类别:
The impact of the built environment on the risk of breast cancer
建筑环境对乳腺癌风险的影响
- 批准号:
7261169 - 财政年份:2007
- 资助金额:
$ 7.06万 - 项目类别:
The impact of the built environment on the risk of breast cancer
建筑环境对乳腺癌风险的影响
- 批准号:
7414771 - 财政年份:2007
- 资助金额:
$ 7.06万 - 项目类别:
Population Sciences and Health Disparities Program
人口科学和健康差异计划
- 批准号:
10624386 - 财政年份:2002
- 资助金额:
$ 7.06万 - 项目类别:
Population Sciences and Health Disparities Program
人口科学和健康差异计划
- 批准号:
10269789 - 财政年份:2002
- 资助金额:
$ 7.06万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 7.06万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 7.06万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 7.06万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 7.06万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 7.06万 - 项目类别: